TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.
Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration. 
Storage
Upon receipt, please store the lyophilized products at -20℃. 
After reconstitution, the stock solution should be kept at -70℃.
Upon receipt, please store the plate at Room Temperature, and please store the buffer at -20℃.